Radiochemical Separation of No-Carrier-Added ¹⁷⁷Lu as Produced via the ¹⁷⁶Yb(n,g)¹⁷⁷Yb®¹⁷⁷Lu Process

N. A. Lebedev², A. F. Novgorodov², R. Misiak³, J. Brockmann¹, F. Rösch¹

¹Institut für Kernchemie, Johannes Gutenberg-Universität, D-55128 Mainz, Germany; ²Laboratory for Nuclear Problems, JINR Dubna, Russia; ³H. Niewodniczanski Institute of Nuclear Physics, 31-342 Cracow, Poland

100


The β emitter ¹⁷⁷Lu (T_{1/2} = 6.71 d, max. and aver. β energies of 421 and 133 keV) is a promising therapeutic radioisotope for the curative treatment of cancer using labelled proteins [1-4]. The decay is accompanied by the emission of low energy γ -radiation with $E_{y} = 208.3 \text{ keV} (11.0\%)$ and 113 keV (6.4%) suitable for simultaneous imaging. Moreover, ¹⁷⁷Lu attracted a special interest because of the very high cross section of 2100 barn of the 176 Lu(n, γ) 177 Lu production process. Irradiation of 100 mg of ^{nat}Lu at reactors providing 10¹⁴ n cm⁻²s⁻¹ for 100 h yields specific activities of 1.15 GBq/µmol, which can be increased by a factor of 35 in the case of 95% isotopically enriched ¹⁷⁶Lu. Nevertheless, a minimum amount of stable ¹⁷⁶Lu cannot be avoided and might cause some problems concerning the labelling of tumour affine biomolecules. Thus, a no-carrier-added (nca) ¹⁷⁷Lu seems to be useful, providing the maximum specific activity of 720 GBq/umol $(1.1 \cdot 10^5 \text{ Ci/g}).$

For this purpose, the alternative production route $^{176} Yb(n,\gamma)^{177} Yb$ $(T_{1/2} = 1.9 h) \longrightarrow \beta^- \rightarrow ^{177} Lu$ was investigated, providing a nea state of $^{177} Lu$. It was the aim of this work to develop an efficient separation of nea $^{177} Lu$ from macroscopic amounts of the ytterbium target material despite of the chemical similarity of these neighboured lanthanides. The separation of the nea $^{177} Lu$ from the macro-amounts of the ytterbium target based on the cementation process, i.e. the selective extraction of Yb by Na(Hg) amalgam from CI / CH₃COO⁻ electrolytes [5-8] followed by a final cation exchange purification.

¹⁷⁷Lu was produced in a neutron capture reaction on natural or isotopically enriched ytterbium. The isotopic composition of isotopically enriched ¹⁷⁶Yb was 0.0034% ¹⁶⁸Yb, 0.114% ¹⁷⁰Yb, 0.634% ¹⁷¹Yb, 1.157% ¹⁷²Yb, 1.014% ¹⁷³Yb, 2.355% ¹⁷⁴Yb and 94.72% ¹⁷⁶Yb. 200 mg (99.9999% chemical purity) Yb₂O₃ were irradiated for 6 h at the TRIGA II reactor Mainz at a neutron flux of $2^{\cdot}10^{12}$ n cm⁻²s⁻¹. 12.4 mg of enriched ¹⁷⁶Yb-Yb₂O₃ were irradiated for two days at the HMI neutron source BERII at 210^{14} n cm⁻² s⁻¹, resulting in 8.1 GBq ¹⁷⁷Lu at one day after EOB. Sodium amalgam was prepared via electrolysis of a 20% solution

of NaOH, as described elswhere [8]. 200 mg Yb₂O₃ were dissolved in 1.4 ml 4 M HCl. Next, 3 ml 4.5 M CH₃COONa and H₂O were added to a total volume of 6 ml of pH \approx 3.4. 4 ml of Na(Hg) amalgam (0.4% Na) were added and this system is stirred for 90 sec. The amalgam is removed from the system. After 4 of these cycles, about 99% of the ytterbium were removed from the aqueous solution. The nca ¹⁷⁷Lu is isolated from this solution by precipitation as the hydroxide using 4 M NaOH. The hydroxide is isolated by centrifugation and dissolved in 2.5 ml 0.1 M HCl. After adding of 2.5 ml 4.5 M CH₃COONa, another 4 œmentations are performed in a new vessel. After this procedure, the amount of Yb^(III) is reduced to about 0.01-0.02 % of the initial mass, cf. Figure 1, while about 85±5% of the nca ¹⁷⁷Lu are remaining in the solution.

In conclusion, the radiochemical separation process developed provides radiochemically pure nca ¹⁷⁷Lu within a total volume of less than 0.5 mL with an overall separation yield of 75±5% within 4-5 h, with Yb contaminations of $< 10^{-6}$ %, i.e. < 1 ng Yb^(III) for a



100 mg 176 Yb target. It thus can be used to synthesise nca 177 Lu labelled radiotherapeuticals.

Figure 1: Successive separation of macro-amounts of Yb^(III) in individual cementation cycles




Figure 2: Ion exchange purification 177 Lu from Yb^(III) using 0.07 M α -HIB, pH 4.7; column: Aminex A6, 2 mm x 80 mm

- [1] Schlomm J, Siler K, Milenic DE et al., 1991. Cancer Res 51, 2889.
- [2] Mulligan T, Carrasquillo JA, Chung Y et al., 1995. Clin Can Res 1, 1447.
- [3] Erion JL, Bugaj JE, Schmidt MA et al., 1999. J Nucl Med 40, 223P.
- [4] Bugaj JE, Erion JL, Schmidt MA et al., 1999. J Nucl Med 40, 223P
- [5] Marsh JK, 1942. J Chem Soc 1, 398 and 523; 1943.J Chem Soc 2, 8 and 531.
- [6] Novgorodov AF, Khalkin VA, Wang Chúang Pén 1966. Radiokhimiya (English trans.) 8, 347; 10, 554.

- [7] Nguen Kong Tsang, Ageev VA, Kolachkovski A et al., 1985. JINR report P6-85-253.
 [8] Denzler F-O, Lebedev NA, Novgorodov AF et al., 1997. J Appl Radiat Isot 48, 319.